Blood Protein Disorders clinical trials

The registry lists 23 studies for Blood Protein Disorders across more than 10 countries. 8 are recruiting or about to start. 1 of them are mainly about Blood Protein Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-29. Counting its 10 narrower conditions too, such as Multiple Myeloma: 4,470 studies, 926 open.

Get an email when these change. Save the Blood Protein Disorders studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 7
Recruiting: 5
Status unknown: 4
Not yet recruiting: 3
Active, not recruiting: 2
Terminated: 1

Phase

Phase 1: 13
Phase 2: 13
Phase 3: 3

Where

United States: 12
Greece: 6
France: 4
United Kingdom: 3
Australia: 3
Spain: 2

Who runs them

Hellenic Society of Hematology (5) · Celgene (2) · Assistance Publique - Hôpitaux de Paris (1) · Amgen (1) · Kelonia Therapeutics, Inc. (1) · Mayo Clinic (1) · Pfizer (1) · Astex Pharmaceuticals, Inc. (1)

What is being tested here

Drugs under test in Blood Protein Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Dexamethasone	4	0	5
Lenalidomide	2	1	4
Daratumumab	2	0	2
Pomalidomide	2	0	2
Isatuximab	1	0	2
Nirogacestat	1	0	1
ARQ531	0	0	1
CLR1404	0	0	1
Elranatamab	0	0	1
At-7519m	0	0	1

Coming up

0phase 3 studies under way

3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Dec 2026A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · OriCell Therapeutics Co., Ltd.
Mar 2027A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma · Kelonia Therapeutics, Inc.
Sep 2027A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Who these studies take

Of the 5 Blood Protein Disorders studies recruiting now, 3 (60%) set no upper age limit and 2 (40%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 5
Age	Women	Men
10	0 (0%)	0 (0%)
18	5 (100%)	5 (100%)
30	5 (100%)	5 (100%)
40	5 (100%)	5 (100%)
50	5 (100%)	5 (100%)
65	5 (100%)	5 (100%)
75	5 (100%)	5 (100%)
85	3 (60%)	3 (60%)

Across all 23 studies, recruiting or not: 17% stop at 75 or younger and 4% at 65; 4% take children; 4% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 23 of 23. search them.